These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
108 related items for PubMed ID: 14453659
1. [Cardiogenic hyperpyruvemia as a manifestation of myocardial metabolism disorder and its medical control]. KANTHER R. Munch Med Wochenschr; 1962 Jan 05; 104():40-5. PubMed ID: 14453659 [No Abstract] [Full Text] [Related]
2. [The influence of cocarboxylase on pyruvic and lactic acids in blood in cardiac disorders]. GREIF S. Wien Med Wochenschr; 1959 Dec 05; 109():975-7. PubMed ID: 13851723 [No Abstract] [Full Text] [Related]
3. [Pyruvic acid level in the blood and attempted use of cocarboxylase (berolase) in circulatory insufficiency]. KARDASZEWICZ S, MASNY N. Pol Tyg Lek; 1961 Jan 30; 16():165-7. PubMed ID: 13751448 [No Abstract] [Full Text] [Related]
4. [Effect of cocarboxylase on hyperlactatemia and hyperpyruvicemia induced by phenformin in dogs]. Valette G, Ribes G, Rondot AM, Loubatières-Mariani MM, Loubatières AL. C R Seances Soc Biol Fil; 1975 Jan 30; 169(1):121-5. PubMed ID: 241466 [Abstract] [Full Text] [Related]
5. [On the problem of therapeutic control of hyperpyruvemic myocardial metabolism disorder]. KANTHER R. Ther Ggw; 1962 May 30; 101():233-6. PubMed ID: 14453660 [No Abstract] [Full Text] [Related]
6. [Efficacy of a mixture of cocarboxylase, DPN, coenzyme A and lipoic acid on hyperpyruvicemia]. MOR F. Minerva Chir; 1961 Apr 30; 16():550-1. PubMed ID: 13772392 [No Abstract] [Full Text] [Related]
7. [The behavior of lactic and pyruvic acids, SGOT and SGPT under persantin treatment]. ALBACH E. Med Welt; 1960 Apr 30; 18():993-6. PubMed ID: 13792332 [No Abstract] [Full Text] [Related]
8. [Importance of cocarboxylases in lowering of hyperpyruvemia in fracture patients]. LODIGIANI E. Prog Med (Napoli); 1953 Jul 15; 9(13):401-5. PubMed ID: 13088958 [No Abstract] [Full Text] [Related]
9. [Clinico-experimental metabolic studies using a Crataegus extract]. Hammerl H, Kränzl C, Pichler O, Studlar M. Arztl Forsch; 1967 Jul 10; 21(7):261-4. PubMed ID: 5631903 [No Abstract] [Full Text] [Related]
14. [Substrate metabolism in the human heart under the effect of hexobendin]. Rudolph W, Marko I. Arzneimittelforschung; 1970 Sep 10; 20(9):1190-8. PubMed ID: 5536795 [No Abstract] [Full Text] [Related]
15. [Study of intermediate glucose metabolism in tuberculosis, with special reference to pyruvic acid and lactic acid in the blood]. Ito M. Iryo; 1966 May 10; 20(5):399-417. PubMed ID: 5336319 [No Abstract] [Full Text] [Related]
17. [On heart therapy with reserpine and Crataegus]. FESER A. Med Klin; 1960 Jul 22; 55():1323-4. PubMed ID: 13822553 [No Abstract] [Full Text] [Related]
18. [Effect of injectable Crataegus extracts on hyperpyruvemias of cardiac genesis]. PIATY R. Wien Klin Wochenschr; 1959 Mar 20; 71(12):213-4. PubMed ID: 13648321 [No Abstract] [Full Text] [Related]
19. [Pyruvates and lactates]. Tarui S, Kuroda K, Nakayama H. Nihon Rinsho; 1967 Aug 20; 25(8):1801-6. PubMed ID: 4874005 [No Abstract] [Full Text] [Related]
20. Red blood cell transketolase activity and blood lactate and pyruvate in patients with cirrhosis of the liver. Presser JI, Farmer M, Shoberg M, Vaamonde CA, Papper S. Digestion; 1971 Aug 20; 4(2):72-80. PubMed ID: 5575290 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]